Merck & (MRK) 10-K Summaries & Annual Filing History
Review Merck & Co., Inc. (MRK) 10-K filings from 2023 through the latest annual report, including business, financial performance, risks, and liquidity.
Key takeaway
Year ended Dec 31, 2025 · FY2025 10-K
Merck's 10-K filing describes its business activities in research, development, and commercialization, with a focus on acquisitions and product launches. The company reported revenue growth and robust net income, but operating cash flow declined due to higher tax and collaboration payments.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$65B
Revenue reported for the fiscal year.
Operating income
n/a
Income from operations reported for the year.
Net income
$18.3B
Net income reported for the year.
Operating cash flow
$16.5B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2022 | $59.3B | +21.7% |
| Dec 31, 2023 | $60.1B | +1.4% |
| Dec 31, 2024 | $64.2B | +6.7% |
| Dec 31, 2025 | $65B | +1.3% |
Business overview
The company engages in research and development, acquisitions, and alliances to support its product portfolio and launch new products. It funds these activities through operating cash flow and maintains a financial profile that enables significant shareholder returns.
Financial performance
Revenue increased compared to the prior year, while net income remained substantial. Operating cash flow decreased from the previous year, primarily due to higher income tax payments and increased upfront payments for collaborations and acquisitions.
Material risks
The company's debt ratio increased, indicating higher leverage. Operating cash flow declined, which may affect future liquidity. Higher tax payments and collaboration-related payments could continue to pressure cash flow.
Liquidity and capital
Merck funds its operations, research, acquisitions, and shareholder returns primarily through operating cash flow. Excess cash is used for business development, capital expenditures, dividends, and share repurchases.
What to watch
Monitor the financial and operational results of the recently acquired Verona Pharma and the new facility from WuXi Vaccin.